SecBot SecBot

AVNS

AVANOS MEDICAL, INC.
NYSE· Orthopedic, Prosthetic & Surgical Appliances & Supplies· Inc. DE· CIK 0001606498 Healthcare & Medical Devices
No price
Market cap
$1.2B
Small cap
Short interest
1.75M
≈3.7% of shares · −1.3%
Days to cover
2.4
at average volume
Insider net
$0
no open-market trades · since Mar 6
New fund stakes
0
Q3 2026 13F · 16 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Mar 6. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q3 2026: 0 added (0 new), 16 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.240 → $0.160 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −1.3% to 1.75M shares. 2.4 days to cover, ≈3.7% of shares.

Who's buying

13F· Q3 2026
0
new positions
16
exits

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action May 2024
Recent actions
DateFirmActionRating
May 7, 2024JMP Securities
REITERATE
REITERATEMarket Perform
Jul 25, 2023Keybanc
DOWNGRADE
DOWNGRADESector Weight
Jun 21, 2023Stifel
REITERATE
REITERATEHold
May 22, 2023CL King
INITIATE
INITIATEBuy
May 4, 2023Morgan Stanley
MAINTAIN
MAINTAINUnderweight
Feb 22, 2023Morgan Stanley
MAINTAIN
MAINTAINUnderweight

Insider ledger

Form 4
$0
open-market buys or sells · since Mar 6
DateInsiderTypeValue
Jul 27, 2026
Galovan Scott Michael
SVP, Chief Financial Officer
Jul 27, 2026
AWARD96,121 sh
Jul 27, 2026
Delgado Sigfrido
SVP, Operations
Jul 27, 2026
AWARD54,886 sh
Jul 27, 2026
Galovan Scott Michael
SVP, Chief Financial Officer
Jul 27, 2026
TO ISSUER$2.4M
Jul 27, 2026
Delgado Sigfrido
SVP, Operations
Jul 27, 2026
TO ISSUER$1.4M
Jul 27, 2026
Galovan Scott Michael
SVP, Chief Financial Officer
Jul 27, 2026
TO ISSUER69,630 sh
Jul 27, 2026
Delgado Sigfrido
SVP, Operations
Jul 27, 2026
TO ISSUER37,520 sh
Jul 27, 2026
Galovan Scott Michael
SVP, Chief Financial Officer
Jul 27, 2026
TO ISSUER21,038 sh
Jul 27, 2026
Delgado Sigfrido
SVP, Operations
Jul 27, 2026
TO ISSUER21,914 sh

Earnings setup

Estimates
$0.16
EPS estimate, this quarter
−33%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Next Q$0.33$0.33–$0.33+0.0%$181.0M
Current FY$1.00$1.00–$1.00+0.0%$710.0M
Next FY$1.25$1.25–$1.25+0.0%$740.0M
Current Q$0.16$0.16–$0.16+0.0%$173.0M

Washington

Corporate Lobbying

9 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Jul 15, 2026
1,751,047
shares short
-1.3%
vs prior settlement
2.4
days to cover
≈3.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 3, 2026 Earnings calendar
AVNS Q3 2026 Earnings Scheduled · 2026-11-03
Sep 30, 2026 Inst.
MORGAN STANLEY · EXIT
0 shares ($0.00)
Sep 30, 2026 Inst.
BlackRock, Inc. · EXIT
0 shares ($0.00)
Jul 27, 2026 SEC
The New York Stock Exchange filed a Form 25-NSE to delist Avanos Medical, Inc. (AVNS) following the completion of its…
25-NSE · Impact 5/10
Jul 27, 2026 Insider
Galovan Scott Michael was granted 96,121 shares
SVP, Chief Financial Officer
Jul 27, 2026 Insider
Delgado Sigfrido was granted 54,886 shares
SVP, Operations
Jul 27, 2026 Insider
Galovan Scott Michael disposed of 96,121 shares
SVP, Chief Financial Officer @ $25.00 ($2.4M)
Jul 2, 2026 SEC
Avanos Medical received all required regulatory approvals for its pending acquisition by American Industrial Partners…
8-K, DEFA14A · Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

7 filings · 3 bullish · 0 bearish · 4 neutral
All AVNS filing & press-release reports (7)